tbuckley/cabot-search huggingface dataset:
Abstract P2-01-10: Immunocytochemistry staining for estrogen and progesterone receptor in circulating tumor cells: Concordance between primary and metastatic tumors.
Authors: FZ Bischoff, T Pham, KL Wong, E Villarin, X Xu, K Kalinsky, JA Mayer
Journal: Cancer Research (2012)

Abstract Introduction: Estrogen (ER) and progesterone receptor (PR)) status is recommended by immunohistochemistry (IHC) and is considered standard practice for selection of treatment options in all breast cancer patients. Because biopsy is not often feasible in every patient presenting with recurrent and/or metastatic disease, circulating tumor cells (CTCs) offer an attractive alternative source of tumor tissue for determining ER/PR status. In addition, CTCs enable monitoring for more effective course of treatment. Experimental Design: Twenty ml of peripheral blood was collected prospectively from 34 patients diagnosed with late stage metastatic/recurrent breast cancer. CTCs were isolated using the microfluidic OncoCEE platform. A cocktail of antibodies was utilized for CTC capture, and detection was accomplished with an expanded anti-cytokeratin (CK) cocktail mixture and anti-CD45. ER/PR protein expression was assessed by immunocytochemistry (ICC) on CK+/CD45- CTCs captured directly within the microchannel and then compared to IHC performed on the primary and/or metastatic tumor. Results: CK+/CD45−/DAPI+ cells were detected in 22 of 34 (65%) patients with late stage breast cancer and assessed for ER/PR immunocytochemistry. Among the 22 cases with one or more CTCs, a concordance of 75% (15/20) and 90% (9/10) in ER/PR status between primary and metastatic tumor was observed, respectively. An overall concordance of 86% (19/22) was achieved. Five cases were discordant based on primary tissue alone; however, two of these cases are concordant when compared to the metastatic biopsy. Thus, only three cases were found to be discordant: all three were positive by IHC on the primary and/or metastatic tumor but negative by CTCs and all three had relatively low numbers of CTCs detected. Conclusions: There is significant heterogeneity of ER/PR protein expression in CTCs and primary/metastatic tumor biopsy. In addition, hormonal status may change over time due to therapy. ER/PR ICC on CTCs using the OncoCEE platform is shown to be feasible, with high concordance (86%) as compared to primary and/or metastatic biopsy (by IHC). The significance of heterogeneity at the ER/PR protein level in CTCs related to the prognosis and predictive response to anti-estrogen therapy needs further evaluation in larger prospective clinical trials. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-01-10.
Case 21-2015
Authors: Soheyla D. Gharib, David L. Berger, Garry Choy, Amelia E. Huck
Journal: New England Journal of Medicine (2015)

Fever developed in a 37-year-old American man living in Vietnam. He was transferred from a local infirmary to an international hospital. A blood culture grew Streptococcus constellatus; fever resolved with antibiotics. The patient was transferred for further evaluation.
Ga-67 Scintigraphy in Acute Leukemia
Authors: N Hod, L Pinkas, Y Volchek, T Horne
Journal: Clinical Nuclear Medicine (2001)

HOD, NIR M.D.,*; PINKAS, LENA M.D.,*; VOLCHEK, YULIA M.D.† AND; HORNE, TIFHA M.D.* Author Information
Unusually Prolonged Pooling of Tc-99m MDP in Varicose Veins
Authors: Marcin R. Roman, Socrates Angelides, Miriam G. Gibson
Journal: Clinical Nuclear Medicine (2001)

Roman, Marcin R. M.B.B.S.; Angelides, Socrates F.R.A.C.P.; Gibson, Miriam G. A.N.M.T. Author Information
THU0366 Efficacy of Adalimumab in Patients with Axial Spondyloarthritis: Results of an Investigator-Initiated 12-Weeks Randomized Double-Blind Placebo Controlled Trial with a 12 Weeks Open-Label Extension Phase
Authors: S. J. Pedersen, IJ Sørensen, AG Loft, JS Hindrup, G Thamsborg, K Asmussen, E Kluger, J Nørregaard, TG Christensen, AG Jurik, JM Møller, M Hasselquist, T Skjødt, D Mikkelsen, M Østergaard
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To investigate the efficacy of adalimumab in patients with axial spondyloarthritis (SpA). <h3>Methods</h3> In this randomized double-blind placebo-controlled trial, 52 patients with axial SpA were allocated to adalimumab 40 mg or placebo subcutaneously every other week for 12 weeks, followed by an open label extension phase of 12 weeks, where all patients received adalimumab. Patients were included if they had 1) SpA according to the ESSG criteria; 2) sacroiliitis on MRI and/or X-rays; 3) BASDAI ≥40 mm despite treatment with NSAIDs. The primary clinical endpoint was a reduction in BASDAI of ≥50% or 20 mm (BASDAI response) and secondary endpoints were ASAS20 and ASAS40 responses. <h3>Results</h3> 27 patients (21 male (78%), median age 41 years (range 23-65), 26 (96%) HLA-B27 positive, disease duration 13 years (1-35), BASDAI 60 mm (IQR: 50-68), CRP 10 mg/l (range: 1.6-50)) were treated with adalimumab 40 mg every other week, and 25 patients (19 (76%) male, age 37 years (23-54), 17 (77%) HLA-B27 positive, disease duration 6 years (1-25), BASDAI 62 (46-72), CRP 5.3 mg/l (1.2-131)(all NS) were treated with placebo. 46 (88%) patients completed weeks 12 and 24. Patients were excluded because of increased disease activity (n=2; placebo), multiple sclerosis (n=1; placebo), infection (n=1; adalimumab) and violation of protocol (n=2; adalimumab/placebo). All patients were excluded before week 12. At week 12, significantly more adalimumab-treated than placebo-treated patients reached an ASAS40 response (p=0.04), whereas numerically more adalimumab-treated patients achieved a BASDAI (48% versus 24%, p=0.07) and ASAS20 (63% vs. 44%, p=0.17) response. Very high responder rates (BASDAI response rates ≥80%) were seen at week 24 in both groups. <h3>Conclusions</h3> Adalimumab is clinically effective for treatment of patients with axial spondyloarthritis. The high response rate may be explained by the patients being younger and with shorter disease duration. <h3>Disclosure of Interest</h3> S. J. Pedersen Grant/research support from: Research support
Megacolon Demonstrated on Colonic Transit Imaging
Authors: CLAYTON FRATER, MONICA A. ROSSLEIGH
Journal: Clinical Nuclear Medicine (1997)

A 33-year-old man underwent a colonic transit study to assist in the assessment of his long-standing constipation. After the oral ingestion of 6 MBq of Ga-67, 10-minute anterior and posterior images of the lower abdomen were performed daily during a 1-week period. After 72 hours, retention of the tracer was markedly abnormal and was confined to an oval pattern, which corresponded to the descending colon. Subsequently, a diagnosis of left-sided megacolon, caused by short-segment Hirschprung's disease, was made.
P70 Improved Lung Cancer Referral Rates And Early Diagnosis In A District General Hospital
Authors: M. Sidhu, A. Gulati, P. Hawkins, S. Cooper
Journal: Thorax (2014)

<h3>Background</h3> Survival rates from lung cancer are poor in England with 5 year survival of 8% of men and 9% of women.<sup>1</sup> We hypothesised that greater awareness of lung cancer symptoms resulting from local (2011) and national (2012) campaigns had increased our 2 week wait (2 WW) referrals and may have led to earlier diagnosis and better survival rates. <h3>Methods</h3> We carried out a retrospective analysis of data between 2008 and 2013 of all patients referred with a new diagnosis of lung cancer. For all new referrals; the number of 2 week GP referrals, patient demographics, treatment modality, survival, and time to first outpatient appointment were examined. <h3>Results</h3> 2 WW referrals increased by 26% from 108 in 2008 to 421 in 2013, (peak 447 in 2012) and the number of confirmed lung cancer cases was 236 and 272 respectively, with 253 in 2012. 29.8% of patients presented as an emergency in 2013 compared to 39.4% in 2008. During 2008 and 2010 4.2(mean)[0.75](SD)% patients presented with stage IA disease compared to 6.3[0.7]% during 2011 and 2013 (p = 0.05). The rate of presentation with stage IV disease did not change significantly (50% vs56.6%, 2008 and 2013 respectively). 15.1% cases underwent curative treatment (surgical) in 2013 compared with 10.1% in 2008. Survival at 6 and 12 months was unchanged. The time to first outpatient appointment was not significantly different (mean of 8 days). <h3>Conclusion</h3> The peak of 2 WW referrals coincided with local and national awareness campaigns. Although there was an increase in 2 WW referrals this was not reflected in the number of confirmed lung cancer cases. However, there has been an increase in the percentage of Stage IA diagnoses and resection rates which may have been a result of the campaigns increasing awareness amongst physicians and leading to earlier referrals. <h3>Reference</h3> Office for National Statistics. Patients diagnosed 2005-2009 and followed up to 2010: Date accessed 12-07-2014. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/mortality/uk-lung-cancer-mortality-statistics
Forced exercise-induced osteoarthritis is attenuated in mice lacking the small leucine-rich proteoglycan decorin
Authors: Tobias Gronau, Karsten Krüger, Carina Prein, Attila Aszodi, Isabel Gronau, Renato V Iozzo, Frank C Mooren, Hauke Clausen-Schaumann, Jessica Bertrand, Thomas Pap, Peter Bruckner, Rita Dreier
Journal: Annals of the Rheumatic Diseases (2016)

Interterritorial regions of articular cartilage matrix are rich in decorin, a small leucine-rich proteoglycan and important structural protein, also involved in many signalling events. Decorin sequesters transforming growth factor β (TGFβ), thereby regulating its activity. Here, we analysed whether increased bioavailability of TGFβ in decorin-deficient (Dcn-/-) cartilage leads to changes in biomechanical properties and resistance to osteoarthritis (OA).Unchallenged knee cartilage was analysed by atomic force microscopy (AFM) and immunohistochemistry. Active transforming growth factor β-1 (TGFβ1) content within cultured chondrocyte supernatants was measured by ELISA. Quantitative real-time (RT)-PCR was used to analyse mRNA expression of glycosaminoglycan (GAG)-modifying enzymes in C28/I2 cells following TGFβ1 treatment. In addition, OA was induced in Dcn-/- and wild-type (WT) mice via forced exercise on a treadmill.AFM analysis revealed a strikingly higher compressive stiffness in Dcn-/- than in WT cartilage. This was accompanied by increased negative charge and enhanced sulfation of GAG chains, but not by alterations in the levels of collagens or proteoglycan core proteins. In addition, decorin-deficient chondrocytes were shown to release more active TGFβ1. Increased TGFβ signalling led to enhanced Chst11 sulfotransferase expression inducing an increased negative charge density of cartilage matrix. These negative charges might attract more water resulting in augmented compressive stiffness of the tissue. Therefore, decorin-deficient mice developed significantly less OA after forced exercise than WT mice.Our study demonstrates that the disruption of decorin-restricted TGFβ signalling leads to higher stiffness of articular cartilage matrix, rendering joints more resistant to OA. Therefore, the loss of an important structural component can improve cartilage homeostasis.
FRI0556 Development of standards of care in spondyloarthritis
Authors: L. Silva, E. Loza, J. Gratacós, J. Sanz, R. Ariza, A. Escudero, L. Linares, M. Moreno, C. Fernández-Carballido, E. De Miguel, P. Zarco, J. Mulero, M. Á. Abad, E. Batlle, R. Queiro, J. C. Torre, J. D. Cañete, J. Rodríguez-Moreno, E. Beltrán, C. Montilla, C. Rodríguez-Lozano, J. J. Aznar, E. Raya, X. Juanola, J. L. Fernández-Sueiro
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Currently, the use of standards of care (SoC) could be the first step to achieve optimal care in patients with spondyloarthritis (SpA). <h3>Objectives</h3> The aim of this project (2e) was to develop evidence-based and user-focused SoC for SpA. <h3>Methods</h3> A RAND-modified Delphi method was applied. First, a systematic literature review of national and international documents covering SOC for SpA was conducted. This included consensus, clinical guidelines and care management documents. Social leagues and health professionals were contacted. All the information retrieved was evaluated by two expert methodologists and, subsequently, adapted and classified according to the three categories of SOC: structure, process and outcomes. A group of 23 experts on SpA was selected and a consensus meeting was held where these SOC were discussed. Afterwards, a first questionnaire round was sent to the experts panel and the SOC were modified according to the results of this round. Finally, a second questionnaire round with the final set of SOC was sent to 167 rheumatologists all around Spain to assess their agreement grade about every SoC. <h3>Results</h3> A total of 38 SoC were set (12 for structure, 20 for process and 6 for outcomes). A selection with the SoC that got highest priority is shown in the table. In general, standards of process achieved high priority whereas standards of result got the lowest grade of agreement. <h3>Image/graph</h3> <h3>Conclusions</h3> The implementation in clinical practice of this set of SoC could help assess and improve the quality of care for patients with SpA. <h3>Disclosure of Interest</h3> None Declared
BT-09 * TRILEXIUM INHIBITS THE EXPRESSION OF t-NOX AND IS A NOVEL, POTENTIALLY POTENT THERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMAS
Authors: A. Kankean, A. Ehteda, A. Chitranjan, M. Tsoli, E. Ager, D. Ziegler
Journal: Neuro-Oncology (2015)

BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a surgically incurable pediatric brain tumour for which no effective treatment has been developed. Benzopyrans are a novel anti-cancer therapy that can initiate several mechanisms of cell death via several pathways including inhibition of tumor-associated NOX (t-NOX). Trilexium is a derivative of simple benzopyrans and is expected to cross the blood brain barrier. We have shown that DIPG cells are sensitive to other agents that inhibit cellular metabolism and we therefore investigated whether Trilexium may represent a novel and effective therapy for DIPG. METHODS: Expression of t-NOX was measured using Western blot in DIPG neurospheres, healthy lung fibroblasts, and normal human astrocytes. Western blots were also used to evaluate the effect of trilexium on t-NOX expression and its mechanism of action. RESULTS: t-NOX expression was observed in DIPG neurospheres and was undetected in normal human astrocytes and fibroblasts. Trilexium inhibited viability across a panel of four independent DIPG patient derived neurospheres in short term culture at nanomolar concentrations, but was ineffective against control non-malignant cells. We found that Trilexium exerts its anti-proliferative effect through the induction of apoptosis with marked increases the levels of cleaved caspase 3 and caspase 8, as well as cleaved PARP following short term treatment. Further, Trilexium suppresses the expression of AKT protein while enhances the phosphorylated p53. CONCLUSION: Our findings indicate that targeting t-NOX with trilexium represents a novel, potentially effective therapy for children with DIPG.
Physician Profiling -- An Analysis of Inpatient Practice Patterns in Florida and Oregon
Authors: H. Gilbert Welch, Mark E. Miller, W. Pete Welch
Journal: New England Journal of Medicine (1994)

Physician profiling is a method of cost control that focuses on patterns of care instead of on specific clinical decisions. It is one cost-control method that takes into account physicians' desire to curb the intrusion of administrative mechanisms into the clinical encounter. To provide a concrete example of profiling, we analyzed the inpatient practice patterns of physicians in Florida and Oregon.
AB0657 Employment status and education attainment in fibromyalgia
Authors: C. E. Gota, B. Nutter, W. S. Wilke
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patients with fibromyalgia have been reported to fare worse socially than the general population. <h3>Objectives</h3> To evaluate the socioeconomic status of fibromyalgia patients seen in a tertiary care center. <h3>Methods</h3> First 306 consecutive new patients enrolled prospectively in the Cleveland Clinic Fibromyalgia Cohort. Enrollment was based on the clinician diagnosis of fibromyalgia. The following demographic data was collected: gender, age, marital data, employment status, estimated income based on ZIP code of residence, type of insurance. Changes in the way ethnicity was reported at the time of enrollment affected our ability to obtain accurate data. <h3>Results</h3> Comparison of our results is made with data on adult US population reported by the Census Bureau and Social Security from 2011 or 2012 where available, presented in parentheses. Employment status and disability: 45% of fibromyalgia patients, median age 44, were employed (vs. 57.3%) 23.4% were unemployed (vs. 8.2%) and 23.8% were receiving disability (vs 15.5%). Educational attainment: High school graduation rate was 94.3% (vs 87.1%), some college was attended by 35.6% (vs 55.9%), 22.5% college graduates (vs 39%), 12% postgraduate education (11.5%). Estimated income: The median estimated income was 40,899 US dollars. Type of insurance: 11.1% had no insurance, 21% were either on medicare or Medicaid while 67.7% had private insurance. <h3>Conclusions</h3> Fibromyalgia is a chronic condition associated with higher disability and unemployement rates. Compared to the general US population less fibromyalgia patients have a college education. <h3>References</h3> http://www.ssa.gov/policy/docs/quickfacts/stat_snapshot/ http://www.census.gov/hhes/socdemo/education/ Reisine S, Fifield J, Walsh S, Forrest DD. Employment and health status changes among women with fibromyalgia: a five-year study. Arthritis Rheum 2008;59(12):1735-41. <h3>Disclosure of Interest</h3> None Declared
Abstract A1-04: The role of chromatin remodeler CHD1 in genomic alterations and prostate cancer progression
Authors: Wennuan Liu, Lindsey Ulkus Rodrigues, Tao Li, Zheng Zhang, Leah Rider, Lina Romero, Lilly S. Zheng, William B. Isaacs, Scott Cramer, Jianfeng Xu
Journal: Cancer Research (2015)

Abstract The chromodomain helicase DNA (CHD) binding proteins have been implicated to play a role in genome stability. CHD1 is second only to PTEN as the most frequent homozygously deleted gene in the tumor genome of prostate cancer (PCa). To assess the role of CHD1 in genomic integrity and PCa progression, we performed a comprehensive survey of DNA copy number alterations (CNAs) in the tumor genome among a total of 611 patients from 5 independent cohorts and an association analysis of CHD1 deletion with cancer progression from low (Gleason 6) to high (Gleason ≥ 8) grade tumors. Our data revealed that the frequency of CHD1 deletion significantly increased as cancer progressing from low to intermediate and to high grades, suggesting a role of this CNA in cancer progression. Loss of CHD1 was significantly associated with homozygous deletions at other genomic locations in the tumor genome, and with deletion of MAP3K7. We next evaluated the in vitro and in vivo joint effects of knockdown of CHD1 and the collaborative gene MAP3K7 on tumorigenesis, cell proliferation (Ki67), tumor size, histopathological characteristics, and cancer progression, using shRNA and tissue recombination with rat urogenital mesenchyme and mouse prostate epithelial stem/progenitor cells grafted under the renal capsule and subcutaneous xenografts in nude mice. While suppressing CHD1 expression, in general, resulted in deceased growth of tumor cells vs. shControl cells, concurrently suppressing expression of both CHD1 and MAP3K7 promoted aggressive tumor growth and reduced survival. We finally explored the effect of knockdown of CHD1/MAP3K7 expression in stable cell lines derived human normal prostate epithelial cells and cancer cells on genomic rearrangement via CNA analysis. Although a wide range of CNAs was observed in different cell lines, some of them recapitulated the CNAs that were commonly observed in the tumors of human PCa. Collectively, these data suggest that loss of CHD1 leads to further evolution of cancer cells via genomic instability and combined loss of CHD1 and MAP3K7 drives the progression of PCa. Note: This abstract was not presented at the conference. Citation Format: Wennuan Liu, Lindsey Ulkus Rodrigues, Tao Li, Zheng Zhang, Leah Rider, Lina Romero, Lilly S. Zheng, William B. Isaacs, Scott Cramer, Jianfeng Xu. The role of chromatin remodeler CHD1 in genomic alterations and prostate cancer progression. [abstract]. In: Proceedings of the AACR Special Conference on Translation of the Cancer Genome; Feb 7-9, 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 1):Abstract nr A1-04.
BM-12 * CEREBRAL INFARCTION SECONDARY TO PULMONARY VEIN COMPRESSION AND LEFT ATRIAL APPENDAGE TUMOR INFILTRATION AS THE PRESENTING SIGN OF METASTATIC SQUAMOUS CELL CARCINOMA OF THE BASE OF THE TONGUE
Authors: B. Dredla, J. Siegel, K. Jaeckle
Journal: Neuro-Oncology (2014)

BACKGROUND: Squamous cell carcinoma of the tongue has been documented to metastasize to the lungs and rarely involve the heart. The majority of documented cases of cardiac metastases are from postmortem analysis. Cases of sudden death, syncope, and dyspnea have been reported. However, stroke and tumor embolization to the brain as the initial clinical presentation has not been documented in the English literature. METHODS: Case Report. RESULTS: This case addresses a 61-year-old male with Stage IVA squamous cell carcinoma of the left tongue base, believed to be in remission after systemic chemotherapy and local radiation, who presented with acute cerebral infarctions involving multiple vascular territories. Cardiac CT obtained during stroke etiology evaluation displayed metastatic disease compressing the pulmonary vein resulting in virtual pulmonary vein thrombus. Transthoracic echocardiogram was negative for cardiac valvular pathology. Anticoagulation was initiated. Twelve days later he returned with recurrent strokes and suspected tumor embolization to the brain. Imaging displayed left atrial appendage structural abnormality highly suggestive of tumor infiltration. CONCLUSION: Cardiac metastases are rare and non-myxomatous tumor embolization to the brain even rarer especially in the setting of cerebral infarction due to pulmonary vein thrombus. Here we describe a case of multiple acute cerebral infarctions appearing from a proximal source refractory to anticoagulation. Thromboembolism from the pulmonary vein and tumor embolization from cardiac metastases are the likely mechanisms for his clinical presentation and radiographic findings. This case demonstrates the complexity of multiple stroke etiologies in one patient and the importance of cardiac imaging in stroke evaluation, particularly in the setting of a patient with a history of cancer.